|
|
Article: Neurocrine Biosciences Announces Positive Phase II Efficacy Results With NBI-34060 Immediate Release (IR) in Elderly Patients With Primary (Chronic) Insomnia; Neurocrine Also announces Pharmacokinetic Results for NBI-34060 Modified Release (MR) Formulation.
- Article from:
- PR Newswire
- Article date:
- December 14, 2001
CopyrightCOPYRIGHT 2001 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO -- Neurocrine Biosciences, Inc. today announced dose related positive efficacy results with all three doses of NBI-34060 Immediate Release (IR) relative to placebo in a Phase II study in the elderly population of primary (chronic) insomnia. This study was a randomized, multi-center, double-blind, placebo-controlled, four-way crossover dose-response study in 42 patients over 65 years of age (mean 70 years, range from 65 to 85 years) with primary (chronic) insomnia. The primary endpoint was Latency to Persistent Sleep (LPS) compared to placebo as measured objectively by polysomnography (PSG). Latency to Sleep Onset (LSO) as reported subjectively by the patient ...